1177 — Sino Biopharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$59.96bn
- HK$66.31bn
- CNY26.20bn
- 96
- 49
- 77
- 90
R2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 24,234 | 23,647 | 26,861 | 26,026 | 26,199 |
Cost of Revenue | |||||
Gross Profit | 19,308 | 18,465 | 21,529 | 21,539 | 21,210 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 18,425 | 18,308 | 21,611 | 20,229 | 19,769 |
Operating Profit | 5,809 | 5,340 | 5,251 | 5,797 | 6,431 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 5,691 | 5,013 | 18,573 | 5,215 | 5,410 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,788 | 4,341 | 16,615 | 4,518 | 4,613 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 2,762 | 2,771 | 14,608 | 2,544 | 2,332 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 2,762 | 2,771 | 14,126 | 2,311 | 2,332 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.147 | 0.147 | 0.762 | 0.097 | 0.101 |
Dividends per Share |